

Checklist for Reporting Human Islet Preparations Used in Research

Manuscript DOI: https://doi.org/10.2337/[insert manuscript submission number] (Example, https://doi.org/10.2337/db18-1234)	
Title: Epigenetic changes in Langerhans islets preceding the onset of diabetes	
Author list: Meriem Ouni, PhD, Sophie Saussenthaler, MSc [*] , Fabian Eichelmann, PhD [*] , Markus Jähnert, MSc, Clemens Wittenbecher PhD, Tina Rönn PhD, Lisa Zellner, MSc, Pascal Gottmann, PhD, Charlotte Ling, PhD, Matthias B. Schulze, DrPH and Annette Schürmann, PhD	
Corresponding author: Prof. Dr. Annette Schürmann	Email address: schuermann@dife.de

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	41	42	43	44	45	46	47	48
Donor age (years)	52	62	55	58	65	52	69	62
Donor sex (M/F)	Female	Male	Female	Female	Male	Female	Male	Male
Donor BMI (kg/m ²)	25.4	35	28.5	25	27.8	27	24.7	20.1

Donor HbA _{1c} or other measure of blood glucose control	38	46	42	39	55	33	40	56
Origin/source of islets ^b	The Nordic Network For Clinical Islet Transplantation							
Islet isolation centre	Uppsala							
Donor history of diabetes? Yes/No	no	yes	yes	no	yes	no	no	yes
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)								
Glucose-lowering therapy at time of death ^c								

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								

Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Yes/No								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results